272 related articles for article (PubMed ID: 32298741)
1. Intussusceptive angiogenesis as a key therapeutic target for cancer therapy.
Saravanan S; Vimalraj S; Pavani K; Nikarika R; Sumantran VN
Life Sci; 2020 Jul; 252():117670. PubMed ID: 32298741
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide signaling regulates tumor-induced intussusceptive-like angiogenesis.
Vimalraj S; Bhuvaneswari S; Lakshmikirupa S; Jyothsna G; Chatterjee S
Microvasc Res; 2018 Sep; 119():47-59. PubMed ID: 29649432
[TBL] [Abstract][Full Text] [Related]
3. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?
Hlushchuk R; Makanya AN; Djonov V
Int J Dev Biol; 2011; 55(4-5):563-7. PubMed ID: 21858777
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide regulates intussusceptive-like angiogenesis in wound repair in chicken embryo and transgenic zebrafish models.
Vimalraj S; Pichu S; Pankajam T; Dharanibalan K; Djonov V; Chatterjee S
Nitric Oxide; 2019 Jan; 82():48-58. PubMed ID: 30439561
[TBL] [Abstract][Full Text] [Related]
5. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
6. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
7. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
8. Redundant angiogenic signaling and tumor drug resistance.
Gacche RN; Assaraf YG
Drug Resist Updat; 2018 Jan; 36():47-76. PubMed ID: 29499837
[TBL] [Abstract][Full Text] [Related]
9. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
Simon T; Gagliano T; Giamas G
Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
[TBL] [Abstract][Full Text] [Related]
10. The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
Battaglin F; Puccini A; Intini R; Schirripa M; Ferro A; Bergamo F; Lonardi S; Zagonel V; Lenz HJ; Loupakis F
Expert Rev Anticancer Ther; 2018 Mar; 18(3):251-266. PubMed ID: 29338550
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of angiogenesis and the angiogenesis/invasion shift.
Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
[TBL] [Abstract][Full Text] [Related]
12. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
Qian CN; Tan MH; Yang JP; Cao Y
Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
14. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors. Drug selectivity and target specificity.
Kesisis G; Broxterman H; Giaccone G
Curr Pharm Des; 2007; 13(27):2795-809. PubMed ID: 17897024
[TBL] [Abstract][Full Text] [Related]
16. Intussusceptive microvascular growth in tumors.
Ribatti D; Djonov V
Cancer Lett; 2012 Mar; 316(2):126-31. PubMed ID: 22197620
[TBL] [Abstract][Full Text] [Related]
17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
18. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
19. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
